MEF2C and neoplasm: Other reported targets include NKIRAS and PTEN in trophoblasts13, two Hsp40 genes (Dnaja2 and Dnajb1) controlling murine Th17 differentiation16, MEF2C during cardiogenesis from embryonic stem cells17, CREBRF during the hypoxia-induced IL-6 response in glioblastoma18, and lymphotoxin-beta (LT-β) a positive regulator of non-canonical NF-kB signalling in MCL where it has tumour suppressing properties19.